Trump’s new tariffs spark uncertainty for India’s pharma exports and stocks; check out how the sector is reacting and what…
Markets today at open, July 31: Markets plunge after Trump’s 25% tariff on Indian imports; track key losers and gainers…
US President Donald Trump has announced a 25 per cent tariff and secondary sanctions on Indian goods starting August 1.…
Jubilant Pharmova reported a 78.66 per cent decline in Q1 profit due to a high base effect, even as revenue…
As Q1FY26 earnings season heats up, Swiggy, Mahindra & Mahindra, ITC, Tata Power, Sun Pharma, UPL, and Maruti Suzuki are…
Dr Gaurav Kharya of Indraprastha Apollo Hospitals explains how stem cell therapies could potentially cure severe Type 1 diabetes. Explore…
Cipla reports 10 per cent rise in net profit to Rs 1,298 crore for Q1FY26 with India business crossing Rs…
While UK tariffs on Indian drugs are already zero, the India-UK Free Trade Agreement is set to boost pharmaceutical and…
In an attempt to pull down drug prices for Americans. Donald Trump played the trade card on Tuesday, issuing a…
Even though the Pharmexcil doesn’t expect delay in the certification timelines, Joshi said that problem is with the transition period.
AbbVie has entered into a $700 million licensing agreement with IGI Therapeutics to co-develop ISB 2001, a promising trispecific T-cell…
Lupin has signed a $50 million licensing deal with Zentiva for the global commercialization of its biosimilar Certolizumab Pegol, targeting…
Nectar Lifesciences’ API and formulation business generated 98.33 percent of the company’s total revenue/ income in the fiscal year 2025.…
Sun Pharma is stepping up regulatory compliance efforts at three USFDA-flagged facilities, including Halol, Mohali, and Dadra.
Apollo Hospitals plans to spin off and list its digital and pharmacy businesses within 18–21 months, aiming to unlock value…
Lupin has received USFDA approval for its ANDA for Prucalopride Tablets, used to treat Chronic Idiopathic Constipation in adults.
Cipla aims for FY26 growth via inorganic expansion and new product launches, especially 2-3 peptide assets. Its FY25 report highlights…
While the Sino Universal Pharmaceuticals will get the necessary regulatory approval from the Chinese authorities, Lupin will be responsible for…